Viewpoint: The Use of Antimycobacterial (Anti‐ MAP ) Therapies in the Treatment of Active Luminal Crohn's Disease

Documenti analoghi

• Primary Gastrointestinal EBV‐Associated Classical Hodgkin Lymphoma in Crohn Disease on Anti‐TNF‐α Therapy: A Rare Association
  di: Katrina Collins, et al.
  Pubblicazione: (2025)
• Induction Efficacy and Safety of Upadacitinib for Active Crohn's Disease in Japanese Patients: A Multicenter Retrospective Study
  di: Takuto Saiki, et al.
  Pubblicazione: (2025)
• Australian Real‐World Effectiveness and Safety of Ustekinumab for the Treatment of Crohn's Disease: Results of the AURORA Study, Including the ANZIBD Consortium
  di: Yoon‐Kyo An, et al.
  Pubblicazione: (2025)
• Stricturing Phenotype Predisposes to Small Bowel and Colorectal Malignancy in Crohn's Disease
  di: Kiran Josy Kanjamala, et al.
  Pubblicazione: (2026)
• Correlation of Point‐of‐Care Intestinal Ultrasound With Endoscopic Disease Severity in Crohn's Disease
  di: Kayal Vizhi Nagarajan, et al.
  Pubblicazione: (2025)